Dr. Alice Berger

LOS ANGELES, Feb. 7, 2018 /PRNewswire/ — Groundbreaking analysis into the early prognosis of lung most cancers and potential new therapies have been awarded funding via two lung most cancers research-focused foundations. Lung Most cancers Basis of America (LCFA) and the Worldwide Affiliation for the Research of Lung Most cancers (IASLC) have partnered to fund the Lori Monroe Scholarship for Lung Most cancers Analysis. These $200,000 grants help promising new analysis led by two feminine scientists, the second 12 months in a row that each Lori Monroe Scholarship recipients go to ladies.

Alice Berger, Ph.D. is an Assistant Member of the Fred Hutchinson Most cancers Analysis Heart and Assistant Professor of Genome Sciences on the College of Washington in Seattle. Her work focuses on feminine lung most cancers sufferers who’ve by no means smoked, and have been recognized with non-small cell lung most cancers (NSCLC).

Christine Lovly, M.D., Ph.D. is an Assistant Professor of Medication with the Division of Hematology-Oncology on the Vanderbilt Ingram Most cancers Heart and Vanderbilt College Faculty of Medication in Nashville. Her work focuses on early detection of small cell lung most cancers (SCLC), and the necessity to develop novel diagnostic and therapy methods for sufferers with this illness, together with liquid biopsies.
“The IASLC is proud to join LCFA in providing these grants to two very promising young investigators. These important research projects will hopefully lead to encouraging results benefiting many lung cancer patients,” stated Dr. Fred R. Hirsch, M.D., Ph.D., CEO of the IASLC.
“The LCFA/IASLC Lori Monroe Scholarship for Lung Cancer Research is the kind of private donor funding that is the lifeline for pioneering researchers like Berger and Lovly to conduct their important work to help give lung cancer patients improved treatment options,” stated Kim Norris, LCFA President and Co-Founder.
Up to now, LCFA and the IASLC have partnered to fund greater than $1.eight million in analysis grants.
The Worldwide Affiliation for the Research of Lung Most cancers (IASLC) is the one world group devoted to the examine of lung most cancers and different thoracic malignancies. Based in 1974, the affiliation’s membership consists of greater than 6,500 lung most cancers specialists throughout all disciplines in over 100 international locations, forming a worldwide community working collectively to overcome lung and thoracic cancers worldwide. The affiliation additionally publishes the Journal of Thoracic Oncology, the first academic and informational publication for matters related to the prevention, detection, prognosis and therapy of all thoracic malignancies. Go to www.iaslc.org for extra info.
About LCFA
LCFA’s mission is the dramatic enchancment in survivorship of lung most cancers sufferers via the funding of transformative science, with the final word objective of curing the illness. Go to lcfamerica.org for the most recent info and to donate.
Press Contacts
Diane Mulligan | dmullligan@mandccommunications.com | 720.273.0927
Becky Bunn | Becky.bunn@iaslc.org |720.325.2946


Please enter your comment!
Please enter your name here